FDA.reportPublic FDA data

DIDANOSINE

Substance profile for UNII K3GDH6OH08, enriched with FDA NDC listings, DailyMed labels, legacy aliases, and open chemistry identifiers.

Chemical structure for DIDANOSINE
Structure render from PubChem CID 50599

Substance Identity#

UNII
K3GDH6OH08
Preferred term
DIDANOSINE
Registry number
69655-05-6
Ingredient type
INGREDIENT SUBSTANCE
Molecular formula
C10H12N4O3
Chemical structure for DIDANOSINE
Structure render from PubChem CID 50599

Chemical And Database Identifiers#

InChIKey
BXZVVICBKDXVGW-NKWVEPMBSA-N
SMILES
OC[C@@H]1CC[C@@H](O1)N2C=NC3=C2N=CNC3=O
RxCUI
3364
PubChem
50599
NCIt
C431
INN ID
6664

Open Chemistry Sources#

Source, Identifier, Link table
SourceIdentifierLink
PubChem Compound50599pubchem.ncbi.nlm.nih.gov/compound/50599
PubChem InChIKey SearchBXZVVICBKDXVGW-NKWVEPMBSA-Npubchem.ncbi.nlm.nih.gov/#query=BXZVVICBKDXVGW-NKWVEPMBSA-N
RxNorm3364mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=3364
NCI ThesaurusC431ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C431
FDA Substance Registration SystemK3GDH6OH08precision.fda.gov/uniisearch/srs/unii/K3GDH6OH08

DailyMed Socrata Ingredients#

Type, DailyMed label, SPL version table
TypeDailyMed labelSPL version
ACTIVE INGREDIENTThese highlights do not include all the information needed to use didanosine delayed-release capsules safely and effectively. See full prescribing information for didanosine delayed-release capsules. Initial U.S. Approval: 19911
ACTIVE MOIETYThese highlights do not include all the information needed to use didanosine delayed-release capsules safely and effectively. See full prescribing information for didanosine delayed-release capsules. Initial U.S. Approval: 19911
ACTIVE MOIETYThese highlights do not include all the information needed to use Didanosine Delayed-Release Capsules Enteric-Coated Pellets safely and effectively. See full prescribing information for Didanosine Delayed-Release Capsules Enteric-Coated Pellets. Initial U.S. Approval: 19912
ACTIVE INGREDIENTThese highlights do not include all the information needed to use Didanosine Delayed-Release Capsules Enteric-Coated Pellets safely and effectively. See full prescribing information for Didanosine Delayed-Release Capsules Enteric-Coated Pellets. Initial U.S. Approval: 19912
ACTIVE INGREDIENTVIDEX (DIDANOSINE) POWDER, FOR SOLUTION [BRISTOL-MYERS SQUIBB COMPANY]16
ACTIVE MOIETYVIDEX (DIDANOSINE) POWDER, FOR SOLUTION [BRISTOL-MYERS SQUIBB COMPANY]16
ACTIVE MOIETYVIDEX EC (DIDANOSINE) CAPSULE, DELAYED RELEASE [BRISTOL-MYERS SQUIBB COMPANY]13
ACTIVE INGREDIENTVIDEX EC (DIDANOSINE) CAPSULE, DELAYED RELEASE [BRISTOL-MYERS SQUIBB COMPANY]13
ACTIVE INGREDIENTDIDANOSINE CAPSULE, DELAYED RELEASE [AUROBINDO PHARMA LIMITED]8
ACTIVE MOIETYDIDANOSINE CAPSULE, DELAYED RELEASE [AUROBINDO PHARMA LIMITED]8
ACTIVE INGREDIENTDIDANOSINE CAPSULE, DELAYED RELEASE PELLETS [BARR LABORATORIES INC.]8
ACTIVE MOIETYDIDANOSINE CAPSULE, DELAYED RELEASE PELLETS [BARR LABORATORIES INC.]8
ACTIVE MOIETYDIDANOSINE (DIDANOSINE ENTERIC-COATED BEADLETS) CAPSULE, DELAYED RELEASE [MYLAN PHARMACEUTICALS INC.]5
ACTIVE INGREDIENTDIDANOSINE (DIDANOSINE ENTERIC-COATED BEADLETS) CAPSULE, DELAYED RELEASE [MYLAN PHARMACEUTICALS INC.]5